Our results are superior to results reported from large multicentre trials (DFS 29-39%). Our study is a relatively large, single-center study involving patients with a low median age at diagnosis. Outcome is often superior in single-center studies compared to multicenter studies, and age is a well-recognized prognostic factor. However, these factors cannot fully account for our favorable results. Our treatment protocol is rather intensive and contains more glucocorticoids, vincristine, L-asparaginase, methotrexate and 6-mercaptopurine than most adult protocols. In this respect, our protocol is in line with pediatric protocols. Favorable outcome for adolescents treated according to pediatric protocols (DFS 64-67%) compared to adult protocols (34-41%) has recently been reported, and the results have been attributed to treatment intensity with particular reference to the drugs specified above. [6] [7] [8] In patients less than 25 years of age, 8-year DFS is 67% in our study. This fits very well with the results reported in studies in which adolescents have been treated according to pediatric protocols.
The Abl tyrosine kinase inhibitor imatinib mesylate (IM) now represents the new standard treatment of chronic myeloid leukemia (CML). 1 However, a growing number of CML patients develop imatinib resistance and several mechanisms of resistance have been described, including BCR-ABL mutations. While most mutant forms are sensitive to new secondgeneration tyrosine kinase inhibitors (TKIs) (dasatinib and nilotinib), the T315I mutation remains completely refractory to imatinib, as well as to these new agents. Homoharringtonine (HHT), a cephalotaxine ester that has demonstrated a clinical activity in myeloproliferative diseases, 3, 4 inhibits protein synthesis and induces cell differentiation and apoptosis. The absence of cross-resistance between HHT and IM in imatinib-resistant leukemic cell lines has been demonstrated, and even a possible synergy between the two compounds has been observed in vitro. HHT decreases the production of the oncogenic kinase BCR-ABL, by inhibition of transcription and translation in the same way in BCR-ABL T315I mutant and in wild-type cell lines.
We report here a CML patient harboring a T315I BCR-ABL mutation while on IM treatment, which completely disappeared when he was treated with HHT.
A 63-year-old man was referred for a chronic-phase Philadelphia-positive (Ph þ ) CML in August 2003. Sokal and Hasford scores led to a high-risk classification. Bone marrow conventional cytogenetic analysis demonstrated a t(9;22) (q34;q11) in 25/25 metaphases analyzed, with no additional chromosomal abnormality. He had no sibling histocompatible donor. The patient was enrolled in the CML French Group phase III prospective trial (SPIRIT) and was randomized to the IM 400 mg þ cytarabine (Ara-C) treatment arm. A complete hematological response (CHR) was achieved within 1 month, while only a minor cytogenetic response was obtained after 1 year of treatment. Despite IM dose escalation to 600 mg daily, the percentage of Ph þ metaphases increased from 53 to 73% after 3 months. The patient was then enrolled in AFR10, a phase I/II prospective study combining IM 600 mg/ day with PegIFN-2a 90 mg subcutaneously weekly. According to the protocol, the patient was serially assessed every 3 months for BCR-ABL mutation detection. After 9 months of the AFR10 treatment, a T315I mutation was detected. IM was immediately discontinued, and PegIFN was continued until obtaining the authorization for compassionate use of HHT. One month after imatinib discontinuation, the patient received three courses of subcutaneous HHT given at 2.5 mg/m 2 /day for 11, 9 and 5 days, respectively. The HHT dose was reduced because of grade 3-4 hematologic toxicity (neutro-penia, thrombocytopenia and anemia). Extra-hematologic adverse events were also observed (grade 1 diarrhea and grade 2 hyperglycemia). The patient then underwent allogeneic hematopoietic stem cell transplantation from an HLA identical 10/10 unrelated donor and unfortunately died from acute grade IV graft-versus-host disease 2 months after transplant.
The T315I mutation was detected in the peripheral blood, accounting for 98% of total BCR-ABL transcripts just before introducing HHT. At that time, the patient was still in stable CHR, in minor cytogenetic response (83% of Ph þ metaphases), and with stable BCR-ABL/GUS transcripts level (Figure 1 ). Serial monitoring of the mutated BCR-ABL T315I versus wild-type BCR-ABL transcripts showed that the mutated transcript decreased to 50% of total BCR-ABL transcripts after 2.5 months of HHT, 2% after 4.5 months and was undetectable after 5.5 months (all samples have been sequenced, we confirmed RFLP results and did not find new mutation acquisition), while the total amount of BCR-ABL transcripts remained stable (Figure 1 ). At this end point, the patient was in CHR, and 100% of Ph þ metaphases in the bone marrow, absence of amplification of the BCR-ABL fusion gene as shown by FISH using the LSI Bcr-Abl ES probe from Abbott and a stable BCR-ABL/GUS ratio were demonstrated (Figure 1) .
CML patients who developed the T315I mutation are of very poor prognosis 5 and they lack alternative therapy, owing to the refractoriness of this mutation to all first and second generation TKIs. In the present case, we observed a T315I-mutated CML patient who not only maintained a hematologic response without disease progression during 6 months but also showed a sharp decrease up to undetectable level of the BCR-ABL T315I mutated clone. The stability of the disease is first an interesting result. Indeed, at 6 months after T315I mutation diagnosis, Nicolini et al. 6 showed that 20% of patients had a disease progression. Second, we observed a rapid and complete disappearance of the mutated transcript after three cycles of semi-synthetic HHT treatment. As the mechanism of action of HHT is the inhibition of protein synthesis without specific target on the BCR-ABL kinase domain, we could hypothesize that the highly proliferative T315I-mutated clone may be particularly sensitive to HHT. Spontaneous reductions of mutated clones related to IM withdrawal were already reported, but to our knowledge, a spontaneous and complete disappearance of a T315I mutation has never been described in the literature to date. Moreover in the present case, the reduction of the BCR-ABL T315I mutated transcript cannot be attributed to the emergence of another non-mutated Ph þ clone, because the percentage of Ph þ metaphases was stable, without any detectable clonal evolution. It is likely that the duration of the HHT treatment was too short to allow a cytogenetic response to occur. The increase of Ph þ metaphases from 80 to 100% after the third cycle of HHT is thought to be related to the dose reduction of HHT (5-day HHT treatment for the last cycle).
In conclusion, the response observed in our patient suggests that HHT can be considered for the treatment of chronic-phase CML disease, despite the presence of BCR-ABL T315I . HHT is an interesting therapeutic option when potential T315I inhibitors such as VX-680 (MK-0457), histone deacetylase inhibitors and decitabine are just at the beginning of clinical development, 7 and when there is no histocompatible donor available. First of all, it is very important to relieve the selective pressure of IM as soon as the T315I mutation is discovered, which necessitates discontinuation of IM therapy. Secondly, considering our present results, several treatment options might be considered, including treatment with HHT, either alone, or in combination with other therapy, as a 'debulking' strategy. HHT is an old treatment, its toxicity is well documented and easy to manage. Until T315I inhibitors are available, HHT could be the initial treatment, to stabilize the disease and even eliminate the T315I clone, before an eventual allogeneic hematopoietic stem cell transplantation, when an HLA-identical related or unrelated donor is identified. Quantification of BCR-ABL transcripts and follow-up of the proportion of mutated transcripts during the follow-up of the BCR-ABL T315I transcripts. Reverse transcription (RT) and quantitative real-time-PCR (RQ-PCR) to amplify BCR-ABL fusion transcript was performed as previously described. 8 The final results are expressed as BCR-ABL/GUS ratios in percentage. The blue curve with squares represents the levels of total BCR-ABL transcripts expressed as BCR-ABL/GUS ratios in percentage according to the international scale 1 (blue log scale, left-hand side). As it was previously described, 8 in order to amplify only the chimeric BCR-ABL fusion transcript allele (and not the normal ABL gene transcript), a first round of PCR was performed on cDNA. The T315I mutation was identified by direct sequencing of both strands of the PCR products obtained. Additional sensitivity for detection of mutations in the setting of minimal residual disease was obtained by two-step RT-PCR. Nested PCR was performed using one-fiftieth of the first PCR product described above. Red curve with down triangles shows the proportion of BCR-ABL mutated transcripts expressed in percentage of total BCR-ABL transcripts (red linear scale, right-hand side). The full (red) and empty (white) circles show the proportion of mutated over germinal alleles, respectively, during evolution. Yellow boxes represent the percentage of Ph þ metaphases. Blue boxes represent the duration of treatment.
Letters to the Editor
Further clinical studies of larger cohorts of mutated T315I CML patients are obviously necessary to clarify the sensitivity of the T315I mutation to HHT in vivo and to guide appropriate therapeutic decisions in these imatinib-resistant CML patients with very poor prognosis. Nevertheless, we are encouraged by the promising results observed with HHT treatment in our patient, which may provide a new alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking. Clinical studies are ongoing.
L Legros 1, 6 , S Hayette JAK2V617F is a recurrent mutation in the classic BCR-ABLnegative myeloproliferative disorders (MPDs); allelic frequency is estimated at 95% for polycythemia vera (PV) and 50% each for essential thrombocythemia (ET) and primary myelofibrosis (PMF). 1 More recently, other JAK2 mutations (exon 12 mutations) have been described in JAK2V617F-negative PV and MPL mutations (MPLW515L/K) in PMF and ET. JAK2V617F occurs in hematopoietic stem cells and myeloid-lineage cells, and some studies have suggested lymphocyte involvement as well: in natural killer, 2 as well as in T and B lymphocytes. 3 However, T-cell involvement was not recognized in many of the initial JAK2V617F studies, 4, 5 including those that used sensitive allele-specific (AS)-PCR assays. 6 Obviously, a negative study in this regard does not exclude the possibility that T-cell involvement is either limited to only a subset of JAK2V617F-positive cases, or is accompanied by an allele burden that is below the limit of detection for a particular mutation screening assay, especially if PCR sequencing is used alone. At the same time, however, the use of ultrasensitive assays could produce false-positive results in the absence of a myeloid cell contamination-free T-cell enrichment process.
To clarify the issue of T-lymphocyte involvement, we prospectively studied four PMF patients harboring MPLW515 mutations (two each with MPLW515L and MPLW515K), and two PV patients harboring homozygous JAK2V617F. The current study was approved by our institutional review board, and all patients provided verbal and written informed consent for study participation. In each case, peripheral blood mononuclear cells (PBMC) were cultured in vitro to yield CD4 þ T lymphocytes. PBMC or granulocytes were isolated by double Ficoll separation as described previously. 5 T-lymphocyte expansion was performed using the Dynabeads s CD3/CD28 T cell expander kit (Dynal, Oslo, Norway), as per protocol. Briefly, previously frozen PBMC were thawed and plated in X-vivo medium (Lonza, Walkersville, MD, USA) with 5% fetal calf serum (FCS) at Figure 1 Purity of in vitro expanded CD4 þ T lymphocytes by flow cytometry analysis. T-lymphocyte population on day 9 is 499.9% pure by CD4 staining.

